Compare Snap On Incorporated (SNA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Viatris Inc — how do they compare? Snap On Incorporated trades at $377.53 (market cap $19.52B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Snap On Incorporated and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| SNA | VTRS | |
|---|---|---|
Market Cap | $19.52B | $18.95B |
Sector | Technology | Health |
52-Week High | $419.31 | $17.86 |
52-Week Low | $324.16 | $9.49 |
Enterprise Value | $19.16B | $31.07B |
Dividend Yield | 2.59% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% on the day, with a bearish technical signal but strong fundamentals including a 19.6% net income margin and 17.58% ROE. Recent Q2 2026 earnings beat estimates with EPS of $4.96, while institutional activity shows mixed positioning. The stock faces resistance near $380 with support at $378.
The outlook is balanced: analyst consensus is bullish with a $473 price target (64.71% buy ratings), but valuation premiums and integration risks from acquisitions like Diesel Laptops pose challenges. Earnings growth and franchise strength support upside, though macroeconomic pressures and execution missteps could hinder performance.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
